The FDA said Ranbaxy is prohibited from making and distributing pharmaceutical ingredients from its facility in Toansa, India "to prevent substandard quality products from reaching US consumers."

The move follows an FDA inspection of the facility which identified significant violations of good manufacturing practices.

Staff at the Toansa facility were found to have retested raw materials and other ingredients after the items failed analytical testing "in order to produce acceptable findings," and did not report or investigate the failures, the FDA said.

The ban is the latest in a series of measures taken by the FDA to keep substandard products made by Ranbaxy out of the US market. The FDA previously banned products from the company's facilities in Paonta Sahib, Dewas and Mohali as part of a consent decree designed to ensure compliance with good manufacturing practices.

The FDA's latest move means Ranbaxy's products are all but entirely banned from US.


Latest News  from Business News Desk